Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Omegaven Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0191

    Fish Oil Triglycerides - Omegaven

    Customize your policy alerts

    Sign up for Cigna Policy IP0191 alerts

    Get alerted when Policy IP0191 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and benefit coverage for Omegaven under Cigna-administered health benefit plans, including coverage for pediatric patients under 18 years of age with established parenteral nutrition-associated cholestasis (PNAC), subject to applicable plan terms and policy criteria.

    Policy Summary
    PayerCigna
    PolicyFish Oil Triglycerides - Omegaven
    Policy CodePolicy IP0191
    Change TypeNo material change
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization for Omegaven when treating a patient under 18 with PNAC.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Prior authorizationUtilization management requirement
    Under 18Age requirement
    1 yearApproval duration
    1 g/kg/dayMaximum daily dose
    B4187

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered HCPCS code
    PNAC preventionNoncovered use

    Medical Necessity Criteria

    Initial therapy - pediatric PNAC

    Omegaven is considered medically necessary when the following is met:

    Covered pediatric PNAC use

    • Indication: Patient has parenteral nutrition-associated cholestasis (PNAC).
    • Age: Patient is less than 18 years of age.<18 years

    Omegaven for prevention of parenteral nutrition-associated cholestasis (PNAC) is not medically necessary.

    Prevention of PNAC is not an indicated or demonstrated use of Omegaven. It has not been demonstrated that Omegaven prevents PNAC in patients dependent on parenteral nutrition.

    Any use of Omegaven outside the covered pediatric PNAC treatment indication is considered not medically necessary. This includes prevention of PNAC and other uses not addressed by the covered indication.

    Covered Coding

    Covered HCPCS CodesHCPCSCovered
    B4187Omegaven, 10 grams lipids

    Authorization and Coverage Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Omegaven. Qualifying approvals are provided for 1 year when the patient has parenteral nutrition-associated cholestasis (PNAC) and meets the age criterion.

    • Approval duration: 1 year
    • Covered indication: parenteral nutrition-associated cholestasis (PNAC)
    • Patient must be less than 18 years of age
    Denial Risk

    Prevention and Other Uses Not Covered

    Omegaven for prevention of PNAC is considered not medically necessary and is not covered. Other uses outside the covered FDA-approved indication may also be denied.

    • Prevention of PNAC is not an indicated or covered use.

    Drug and Clinical Background

    Omegaven is an intravenous fish oil triglyceride emulsion indicated as a source of calories and fatty acids for pediatric patients with established parenteral nutrition-associated cholestasis (PNAC).

    Clinical Definition

    Parenteral nutrition-associated cholestasis (PNAC)
    ConditionParenteral nutrition-associated cholestasis (PNAC)
    Clinical contextAn established cholestatic condition occurring in pediatric patients receiving parenteral nutrition
    Approved role of OmegavenIndicated as a source of calories and fatty acids in pediatric patients with PNAC; it is not indicated for prevention of PNAC

    Initial Approval for Pediatric PNAC

    Initial approval for pediatric PNAC

    Prior authorization is required for benefit coverage. Approve for 1 year when all of the following are met:

    Initial authorization criteria

    • Diagnosis: Patient has parenteral nutrition-associated cholestasis (PNAC).
    • Age requirement: Patient is less than 18 years of age.<18 years

    Dose and Quantity Limits

    Omegaven Pediatric Daily Dose
    PopulationPediatric patients
    Recommended daily dose1 g/kg/day
    Maximum daily dose1 g/kg/day
    Policy Summary
    PayerCigna
    PolicyFish Oil Triglycerides - Omegaven
    Policy CodePolicy IP0191
    Change TypeNo material change
    Effective DateNov 15, 2026
    Last ReviewOct 8, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization for Omegaven when treating a patient under 18 with PNAC.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered CodingAuthorization and Coverage ActionsDrug and Clinical BackgroundClinical DefinitionInitial Approval for Pediatric PNACDose and Quantity Limits
  1. Omegaven for any other use is considered not medically necessary; the noncovered-use list may not be all-inclusive.
  2. Billing Rule

    Criteria or Coding Mismatch May Result in Denial

    Claims may be denied when the covered indication, age criterion, or coding does not match the policy requirements. Verify that Omegaven is being used for PNAC in a patient younger than 18 and that the claim uses the applicable code.

    • Covered indication: parenteral nutrition-associated cholestasis (PNAC), not prevention of PNAC.
    • Age criterion: patient must be less than 18 years of age.
    • Applicable HCPCS code: B4187 — Omegaven, 10 grams lipids.
    • Codes that are deleted or not effective on the date of service may not be eligible for reimbursement; the code list may not be all-inclusive.